Missing Script · Evidence review
Fasting is one of those subjects where the biology is interesting and the advice can get ahead of the evidence. I think we should take the research seriously. We should take the person trying to get through treatment just as seriously.
The ovarian cancer trial worth discussing
At the 2026 ASCO Annual Meeting, abstract 5517 reported a single-center randomized pilot involving 36 women with advanced high-grade serous ovarian cancer receiving carboplatin/paclitaxel before surgery.
Eighteen were assigned usual eating; eighteen fasted from 36 hours before until 24 hours after chemotherapy. The research regimen permitted fluids and up to 350 calories daily, with normal eating between cycles. This describes the experiment, not instructions to copy it.
The primary endpoint, change in insulin, favored fasting. Among patients undergoing surgery, complete or near-complete pathological response occurred in 10 of 17 versus 3 of 17. Reported median progression-free survival was 38 versus 24 months, with median follow-up of only 18 months.
That is an encouraging signal. It is also a conference abstract with a tiny sample and immature survival follow-up. Progression-free survival measures time until worsening or death; it does not establish longer overall survival or cure. Replication matters.
ASCO reported that all fasting participants completed treatment and common blood-count toxicities were similar between groups. That cannot establish safety for someone already malnourished.
Other recent trials answer different questions
Daily eating windows, short fasts around chemotherapy and fasting-mimicking diets are different interventions. Their results are not interchangeable.
A January 2026 breast cancer report assessed nightly fasting, metformin and nutrition counseling before surgery in hormone receptor-positive invasive cancer or DCIS. In the first 14 intervention participants, there were no dose-limiting toxicities. This was preliminary safety evidence, not proof of cancer benefit; a combined intervention cannot isolate fasting’s contribution.
A 2025 systematic review likewise found insufficient robust evidence for firm conclusions about treatment effectiveness or side-effect reduction.
Where longevity and mTOR fit
mTOR is part of the machinery linking nutrient availability to cell growth and protein production. Turning it down is not automatically beneficial everywhere. In a 2014 study of eight healthy men, a 72-hour fast reduced muscle mTOR signaling alongside increased net muscle protein loss. That small mechanistic experiment cannot predict every fasting schedule, but it challenges the idea that lower mTOR is always better.
A 2024 analysis of fasting-mimicking diet trials reported an approximately 2.5-year decrease in estimated median biological age after three monthly cycles. These involved five-day, plant-based, low-calorie, low-protein diets in adults, not people undergoing chemotherapy.
Those were secondary and exploratory biomarker analyses. A laboratory-based age estimate is not 2.5 extra years of life. These human studies did not demonstrate lifespan extension. Nor does changing mTOR prove that a tumor is being controlled.
The safety conversation comes first
ESPEN’s 2021 cancer nutrition guidance advises against energy restriction in people with or at risk of malnutrition and does not recommend fasting around anticancer treatment. It predates the ovarian study; one pilot does not settle those concerns.
Ask an oncology dietitian to assess intake, weight and muscle. Poor appetite, vomiting, dehydration or frailty deserve assessment before restriction. Review diabetes medications, especially insulin, and every medicine’s food requirements. Do not change treatment or medication timing yourself. Pregnancy, breastfeeding and an eating-disorder history are additional reasons to avoid fasting.
Questions for the care team
- Does this research match my cancer, treatment and nutritional condition?
- Would a supervised clinical trial be available?
- How would we protect muscle, hydration and treatment delivery?
There is room for curiosity here. There should also be room to eat without feeling you are missing your chance to help yourself.
Evidence checked October 3, 2026. Educational discussion; review personal treatment decisions with your care team.
